Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11092MR)

This product GTTS-WQ11092MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11092MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2120MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ8982MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ9175MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ11130MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ10870MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ7634MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ11308MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ12985MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW